Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
Back

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Not Recruiting

Open to: FEMALE

Age: 18.0 - 130.0

Cambridge Sutton Leeds London Manchester Sutton

Medical Conditions

Breast Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Oct 2018 Sep 2024

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Part A: AZD9833 monotherapy dose escalation.

Intervention Arm Group : AZD9833 monotherapy dose escalation;

Intervention Type : DRUG
Intervention Description : Part B: AZD9833 monotherapy expansion.

Intervention Arm Group : AZD9833 monotherapy dose expansion;

Intervention Type : DRUG
Intervention Description : Part C: AZD9833 in combination with palbociclib dose escalation

Intervention Arm Group : AZD9833 with palbociclib dose escalation;

Intervention Type : DRUG
Intervention Description : Part D: AZD9833 in combination with palbociclib expansion

Intervention Arm Group : AZD9833 with palbociclib dose expansion;

Intervention Type : DRUG
Intervention Description : Part E: AZD9833 in combination with everolimus dose escalation

Intervention Arm Group : AZD9833 with everolimus dose escalation;

Intervention Type : DRUG
Intervention Description : Part F: AZD9833 in combination with everolimus dose expansion

Intervention Arm Group : AZD9833 with everolimus dose expansion;

Intervention Type : DRUG
Intervention Description : Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation

Intervention Arm Group : AZD9833 with abemaciclib (± anastrozole) dose escalation;

Intervention Type : DRUG
Intervention Description : Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion

Intervention Arm Group : AZD9833 with abemaciclib (± anastrozole)dose expansion;

Intervention Type : DRUG
Intervention Description : Part I: AZD9833 in combination with capivasertib dose escalation

Intervention Arm Group : AZD9833 with capivasertib dose escalation;

Intervention Type : DRUG
Intervention Description : Part J: AZD9833 in combination with capivasertib dose expansion

Intervention Arm Group : AZD9833 with capivasertib dose expansion;

Intervention Type : DRUG
Intervention Description : Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation

Intervention Arm Group : AZD9833 with ribociclib (± anastrozole) dose escalation;

Intervention Type : DRUG
Intervention Description : Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion

Intervention Arm Group : AZD9833 with ribociclib (± anastrozole) dose expansion;

Intervention Type : DRUG
Intervention Description : Part M: AZD9833 in combination with anastrozole dose escalation

Intervention Arm Group : AZD9833 with anastrozole dose escalation;

Intervention Type : DRUG
Intervention Description : Part N: AZD9833 in combination with anastrozole dose expansion

Intervention Arm Group : AZD9833 with anastrozole dose expansion;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    Cambridge
    CB2 0QQ
  • Research Site
    Sutton
    SM2 5PT
  • Research Site
    Leeds
    LS9 7TF
  • Research Site
    London
    SW2 6JJ
  • Research Site
    Manchester
    M20 4GJ
  • Research Site
    Sutton
    SM1 2DL


The study is sponsored by AstraZeneca




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03616587
Last updated 01 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top